… metastatic breast cancer is based on the rationale that survival depends upon the metastatic
disease burden and local therapy will not impact overall survival (OS). Thus the therapeutic …

… We report survival data for a consecutive case series of advanced metastatic breast cancer
patients who received a comprehensive clinical program combining conventional treatments …

… and without trastuzumab therapy on survival since first diagnosis of metastases is unclear. …
on survival in metastatic breast cancer in our cohort. All patients with primary breast cancer …

… metastatic breast cancer receiving modern systemic therapy is unknown. Similarly, the clinical
relevance of occult CNS metastasis, survival … (CNS) metastasis in breast cancer based on …

… for a survival benefit amongst patients with metastatic breast cancer who participated in a …
psychotherapy and improved survival time amongst metastatic cancer patients has not been …

… on survival from cancer, 66 women with metastatic breast cancer, all … No significant difference
was found in survival post-… were significant predictors of survival: metastatic site, hormonal …

… In this analysis of SEER data, patients with brain metastases had substantially shorter
median overall survival of 10 months compared with 30 months for patients without brain …

… treatment has extended survival of breast cancer over the … survival benefit is achieved once
metastases have occurred. This study investigates survival trends in metastatic breast cancer …

… Survival in this paper refers to survival from the initiation of FAC treat ment, and the results …
to survival from diagnosis of primary breast cancer or survival from the time first metastasis (or …

… with anti-HER2 therapy in the metastatic setting was performed. Cox proportional hazards …
long-term survival. Median overall survival from the time of breast cancer recurrence was 3.9 …